RE:RE:RE:RE:RE:Q3. Furthermore, 70c a share is a market cap of 300m. When you factor in epidiolex sales numbers in the U.S, and the massive chunk first to Market generics take of that...6month no competition prize for first to market generics enforced by the FDA....I cannot find any other Corp with the certs/facility to bring this to market today...it's not unreasonable to project 100m easy for the MPL top line...based on the submission of the DMF, timelines associated with ANDA's, Jazz settling with the majority of the ANDA applicants. It's not far fetched to think MPL will be first to the party...add on Keith's comments about "preparing for epidiolex launch in the U.S" Q1...I'm waiting for my 70c a share.